University of Cincinnati Cancer Institute
Cincinnati, Ohio 45267-0502
3 studies enrolling now · 43 studies all time
What they study most
Acute Kidney Injury Due to Sepsis, Adenocarcinoma, Pancreatic Ductal, Advanced Adult Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignancies, Advanced Solid Tumor, Autism-Related Irritability, Bladder Cancer, Bone Neoplasms, Brain Cancer, Brain Neoplasms, Adult, Malignant, Brain Tumor
Studies at this site
- A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer — Recruiting now
- A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC — Recruiting now
- EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma — Recruiting now
- A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively — Recruiting now
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas — Recruiting now
- A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma — Running, not enrolling
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) — Running, not enrolling
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Running, not enrolling
- Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM — Completed
- Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) — Stopped early
- Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers — Completed
- Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma — Completed
- A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer — Completed
- RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) — Completed
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer — Stopped early
- Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma — APPROVED_FOR_MARKETING
- Phase IIB TL + YCWP + DC in Melanoma — Completed
- SGI-110 in Combination With Carboplatin in Ovarian Cancer — Completed
- Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer — Running, not enrolling
- A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib — Completed
- Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma — Completed
- (Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI — Stopped early
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis — Stopped early
- Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. — Completed
- A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC — Status unconfirmed
- Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma — Completed
- Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer — Completed
- INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Withdrawn before enrolling
- Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma — Stopped early
- Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy — Stopped early
- Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas — Completed
- Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma — Completed
- Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma — Completed
- Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer — Status unconfirmed
- Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 — Stopped early
- Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma — Completed
- A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma — Completed
- Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors — Completed
- Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck — Stopped early
- Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid — Completed
- PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy — Completed
- Safety Study of SGN-CD70A in Cancer Patients — Completed
- Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma — Completed